SAVA Stock Summary and Trading Ideas (Cassava Sciences | NASDAQ:SAVA)

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.

Cassava Sciences trades on the NASDAQ stock market under the symbol SAVA.

As of April 18, 2024, SAVA stock price declined to $21.19 with 934,218 million shares trading.

SAVA has a beta of 0.61, meaning it tends to be less sensitive to market movements. SAVA has a correlation of 0.01 to the broad based SPY ETF.

SAVA has a market cap of $916.38 million. This is considered a Small Cap stock.

In the last 3 years, SAVA stock traded as high as $146.16 and as low as $12.32.

The top ETF exchange traded funds that SAVA belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.

SAVA has underperformed the market in the last year with a return of -14.2%, while the SPY ETF gained +22.3%. In the last 3 month period, SAVA fell short of the market, returning -16.4%, while SPY returned +6.1%. However, in the most recent 2 weeks SAVA has outperformed the stock market by returning +3.0%, while SPY returned -3.8%.

SAVA support price is $20.11 and resistance is $22.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SAVA stock will trade within this expected range on the day.